Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma

Fig. 3

In vivo biomimetic NP targeting and biodistribution. Representative images of Lipo and Leuko NP accumulation within orthotopic osteosarcoma tumor after 1 h by IVM showing vessels (green), tumor cells (red) and NP (white) (a) and quantification of Lipo and Leuko accumulation within the tumors (Leuko in red, Lipo in green) (b) *p < 0.02. Lipo and Leuko NPs accumulation speed within the tumor in vivo during the first 60 min after injection as observed with IVM (c). Representative fluorescent imaging of Lipo and Leuko Cy7-labeled NPs localization in the tumor after 1–6–24 h (d) and quantification of fluorescence intensity of regions-of-interest (ROI). (Leuko in red, Lipo in green) (e) *p < 0.05. Quantification of fluorescence intensity of regions-of-interest (ROI) of NP biodistribution in mice organs (Leuko in red, Lipo in green) (f). *p < 0.05. Histological section of organs after 24 h of NP IV injections compared to control (no treatment). All sections were stained with hematoxylin–eosin (g). Scale bar = 10 μm

Back to article page